FLORINEF

This brand name is authorized in Australia, Canada, Estonia, Finland, Hong Kong, Japan, Netherlands, New Zealand, Singapore

Active ingredients

The drug FLORINEF contains one active pharmaceutical ingredient (API):

1 Fludrocortisone UNII V47IF0PVH4 - FLUDROCORTISONE ACETATE

Fludrocortisone, in very small doses, maintains life in adrenalectomised animals, enhances the deposition of liver glycogen and produces thymic involution, eosinopenia, retention of sodium and increased urinary excretion of potassium. Read about Fludrocortisone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H02AA02	Fludrocortisone	H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN → H02AA Mineralocorticoids
Discover more medicines within H02AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 1433K
Country: CA	Health Products and Food Branch	Identifier(s): 02086026
Country: EE	Ravimiamet	Identifier(s): 1091461, 1284409, 1706442
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 183871
Country: HK	Department of Health Drug Office	Identifier(s): 00036
Country: JP	医薬品医療機器総合機構	Identifier(s): 2452003F1035
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 15431
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 6409
Country: SG	Health Sciences Authority	Identifier(s): 10680P